New hope for lymphoma patients who Can't take chemo
NCT ID NCT04417166
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab (Keytruda) with targeted radiation can control a rare type of lymphoma called NK/T-cell lymphoma. It enrolls 30 patients with early-stage disease who are not healthy enough for standard chemotherapy. Participants receive radiation plus pembrolizumab every 3 weeks, followed by up to 2 years of maintenance therapy. The main goal is to see how many patients remain cancer-free after 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (Keytruda) and radiation therapy
- What this could lead to
- If successful, this combination could offer an effective chemotherapy-free treatment option for patients with this rare lymphoma who cannot tolerate standard chemo.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The long-term safety and effectiveness are still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, EXTRANODAL NK-T-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Rui-Jin Hospital
Shanghai, 200025, China
-
Sun Yat-sen University Cancer Center
Guangzhou, China